Trial Profile
A study to evaluate and compare the anti-Xa activity and serum levels in patients receiving Apixaban 5 mg twice daily or rivaroxaban 20 mg once daily
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2017
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Therapeutic Use
- 30 Oct 2017 New trial record
- 01 Oct 2017 Results published in the Annals of Pharmacotherapy